van Westrhenen R, Birkenhäger T K
Tijdschr Psychiatr. 2022;64(5):312-316.
Medication side effects and limited efficacy are substantial problems in general and also in psychopharmaceuticals. Previous studies have shown that pharmacogenetic individual characteristics can be relevant.
To arrive at a responsible use of pharmacogenetics, exploiting its potential but also avoiding overdiagnosis.
To provide an overview of the current status quo in the field of pharmacogenetics in psychiatry.
The Dutch Association for Psychiatrists (NVvP) authorized a guideline ‘Pharmacogenetics in Psychiatry’ that is summarized. Also the current international guidelines and clinical implementation of pharmacogenetics are discussed.
For the time being, pharmacogenetics seems to be indicated only when patients have already experienced problems with psychopharmaca use, such as side effects and/or inefficacy. If genotyping is requested then generally CYP2C19 and CYP2D6 can be useful, as dosage recommendations are available in case of genetic variants.
药物副作用和疗效有限在一般情况下是重大问题，在精神药物领域也是如此。先前的研究表明，药物遗传学个体特征可能与之相关。
合理运用药物遗传学，发挥其潜力同时避免过度诊断。
概述精神病学领域药物遗传学的当前现状。
荷兰精神病医生协会（NVvP）批准了一份“精神病学中的药物遗传学”指南并进行了总结。还讨论了当前药物遗传学的国际指南和临床应用。
目前，似乎仅当患者在使用精神药物时已经出现问题，如副作用和/或无效时，才表明需要进行药物遗传学检测。如果要求进行基因分型，那么一般来说CYP2C19和CYP2D6可能有用，因为对于基因变异情况有可用的剂量建议。
